DDInter255 DDInter1105
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent found in extracts of the tunicate _Ecteinascidia turbinata_, with the primary difference being the substitution of the tetrahydroisoquinoline with a tetrahydro β‐carboline that results in increased antitumour activity of lurbinectedin as compared to its predecessor. On June 15, 2020, the FDA granted accelerated approval and orphan drug designation to lurbinectedin for the treatment of adult patients with metastatic SCLC who have experienced disease progression despite therapy with platinum-based agents. This accelerated approval is based on the rate and duration of therapeutic response observed in ongoing clinical trials and is contingent on the verification of these results in confirmatory trials.
Busulfan {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Fludarabine
Fludarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Busulfan {u} (Compound) downregulates {v} (Gene) DCK
DCK {u} (Gene) is bound by {v} (Compound) Fludarabine
Fludarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Busulfan {u} (Compound) causes {v} (Side Effect) Myalgia
Myalgia {u} (Side Effect) is caused by {v} (Compound) Fludarabine
Fludarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Busulfan {u} (Compound) downregulates {v} (Gene) DCK
DCK {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Busulfan {u} (Compound) downregulates {v} (Gene) DCK
DCK {u} (Gene) is bound by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Busulfan {u} (Compound) downregulates {v} (Gene) DCK
DCK {u} (Gene) is downregulated by {v} (Compound) Crizotinib
Crizotinib {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Busulfan {u} (Compound) causes {v} (Side Effect) Pericardial effusion
Pericardial effusion {u} (Side Effect) is caused by {v} (Compound) Imatinib
Imatinib {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Busulfan {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Busulfan {u} (Compound) downregulates {v} (Gene) KIAA0907
KIAA0907 {u} (Gene) is upregulated by {v} (Compound) Clofarabine
Clofarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Busulfan {u} (Compound) upregulates {v} (Gene) PSRC1
PSRC1 {u} (Gene) is downregulated by {v} (Compound) Clofarabine
Clofarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lurbinectedin
Busulfan (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Fludarabine (Compound) and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Busulfan (Compound) downregulates DCK (Gene) and DCK (Gene) is bound by Fludarabine (Compound) and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Busulfan (Compound) causes Myalgia (Side Effect) and Myalgia (Side Effect) is caused by Fludarabine (Compound) and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Busulfan (Compound) downregulates DCK (Gene) and DCK (Gene) is downregulated by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Busulfan (Compound) downregulates DCK (Gene) and DCK (Gene) is bound by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Lurbinectedin
Busulfan (Compound) downregulates DCK (Gene) and DCK (Gene) is downregulated by Crizotinib (Compound) and Crizotinib may lead to a major life threatening interaction when taken with Lurbinectedin
Busulfan (Compound) causes Pericardial effusion (Side Effect) and Pericardial effusion (Side Effect) is caused by Imatinib (Compound) and Imatinib may lead to a major life threatening interaction when taken with Lurbinectedin
Busulfan (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Lurbinectedin
Busulfan (Compound) downregulates KIAA0907 (Gene) and KIAA0907 (Gene) is upregulated by Clofarabine (Compound) and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Busulfan (Compound) upregulates PSRC1 (Gene) and PSRC1 (Gene) is downregulated by Clofarabine (Compound) and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin